Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi or parasites change over time and stop responding to medicines. Resistant infections become harder to treat, increase the risk of disease spread and can make routine surgery, cancer treatment and intensive care more dangerous. For UPSC, AMR links public health, science and technology, agriculture, environment, governance and international cooperation.
What Is Antimicrobial Resistance?
Antimicrobials are medicines used to prevent and treat infectious diseases in humans, animals and plants. They include antibiotics, antivirals, antifungals and antiparasitic medicines. Antibiotics are the subgroup used against bacterial infections.
AMR develops when microorganisms survive exposure to a medicine that previously controlled or killed them. The resistant organism—not the patient—becomes resistant. The term antibiotic resistance refers specifically to resistance in bacteria, while antimicrobial resistance covers bacteria, viruses, fungi and parasites.
Microorganisms with resistance to several medicines are often called superbugs. Their spread can make common infections difficult or sometimes impossible to treat, leading to longer illness, prolonged hospital stays, costlier treatment, disability and death.
Why Is AMR a Major Public-Health Concern?
- Large mortality burden: global estimates for 2019 attributed about 1.27 million deaths directly to bacterial AMR and associated it with approximately 4.95 million deaths.
- Threat to modern medicine: effective antimicrobials support surgery, organ transplantation, chemotherapy, neonatal care and treatment of severe infections.
- Economic pressure: resistant infections require longer treatment, more expensive second-line medicines, laboratory support and additional hospital care.
- Cross-border risk: resistant pathogens and resistance genes can spread through travel, trade, food systems, animals, water and healthcare networks.
- Unequal impact: weak sanitation, limited diagnostic facilities and poor access to suitable medicines make low-resource settings especially vulnerable.
AMR in India
India carries a high burden of infectious disease and has extensive antimicrobial use across human health and animal production. This makes the country central to the global response. The ICMR Antimicrobial Resistance Surveillance and Research Network has monitored resistance through participating laboratories since 2013.
The ICMR surveillance report for January–December 2024 analysed 99,027 culture-positive isolates from its network. Gram-negative bacteria remained prominent in clinically relevant samples, with Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii among the important pathogens. Because these data come mainly from tertiary-care hospitals, they should not be treated as a direct estimate of resistance in the wider community.
India's policy response has progressed from the National Policy for Containment of Antimicrobial Resistance in 2011 and the first National Action Plan in 2017 to National Action Plan on AMR 2.0 for 2025–2029. The updated plan follows a One Health approach and brings human health, animal health, food, agriculture and the environment into a common framework.
What Drives Antimicrobial Resistance?
Misuse and overuse in human health
- Taking antibiotics for viral illnesses such as influenza, against which antibiotics do not work.
- Self-medication, over-the-counter purchase and use without qualified medical advice.
- Incorrect dose or duration, sharing medicines and not following the prescribed treatment plan.
- Unnecessary use of broad-spectrum antibiotics when a targeted medicine would be suitable.
Prescribing without adequate diagnosis
When rapid and affordable diagnostics are unavailable, treatment may be based only on symptoms. Empirical treatment is sometimes clinically necessary, but repeated avoidable use of broad-spectrum medicines increases selection pressure. Laboratories, culture testing and antimicrobial-stewardship programmes help clinicians choose the right medicine, dose and duration.
Use in animals and food production
Routine or poorly controlled antimicrobial use in livestock, poultry and aquaculture can select resistant organisms. They may reach people through food, direct contact or environmental pathways. Better animal husbandry, vaccination, biosecurity and veterinary oversight reduce dependence on antimicrobials.
Poor infection prevention
Unsafe water, inadequate sanitation, low vaccination coverage, weak hospital infection control and overcrowding increase infections. More infections mean greater antimicrobial use and more opportunities for resistance to emerge and spread.
Environmental and pharmaceutical pollution
Antibiotic residues and resistant organisms can enter soil and water through manufacturing waste, hospital discharge, sewage and agricultural runoff. The environment can then act as a reservoir and transmission pathway for AMR.
WHO Guidance on Antibiotic-Manufacturing Pollution
In September 2024, the World Health Organization issued its first global guidance on wastewater and solid-waste management for antibiotic manufacturing. It provides health-based targets and risk-management practices for regulators, procurers, inspectors, manufacturers and waste-management services.
The guidance matters because quality standards have traditionally focused on the medicine supplied to patients, while environmental emissions from production have often received less attention. Controlling antibiotic discharge, auditing facilities and improving transparency can reduce the conditions in which resistant bacteria emerge and spread without restricting equitable access to quality-assured medicines.
How India Is Responding to AMR
| Measure | Purpose |
|---|
| NAP-AMR 2.0 (2025–2029) | Coordinates action across human, animal, food, agriculture and environmental sectors through a One Health approach. |
| ICMR AMR Surveillance and Research Network | Tracks pathogen susceptibility and resistance patterns and supports evidence-based treatment guidance. |
| Prescription and dispensing controls | Promote documented clinical indication, rational prescribing and compliance with rules governing antibiotic sales. |
| Antimicrobial stewardship | Encourages the right drug, dose, route and duration, supported by diagnostics and periodic review. |
| Infection prevention and vaccination | Reduces infections and therefore reduces the need for antimicrobial treatment. |
| Regulation of agricultural use | Includes restrictions such as the prohibition of colistin as a growth promoter in food-producing animals. |
| Research and innovation | Supports new antibiotics, diagnostics, vaccines and alternative therapies while protecting the effectiveness of existing drugs. |
One Health Approach to AMR
AMR cannot be controlled by hospitals alone. Human health is connected with animal health, food systems and the environment. A One Health response therefore requires coordination among doctors, veterinarians, microbiologists, farmers, pharmaceutical manufacturers, urban bodies, pollution regulators and communities.
- Human health: diagnostics, stewardship, infection control and responsible access to essential medicines.
- Animal health: veterinary supervision, vaccination, biosecurity and limits on non-therapeutic antimicrobial use.
- Food and agriculture: safer production, residue monitoring and hygienic supply chains.
- Environment: treatment of sewage, hospital effluent and manufacturing waste, supported by surveillance of resistant organisms and genes.
Can Artificial Intelligence Help Discover New Antibiotics?
Artificial intelligence can screen genomic and microbiome data much faster than conventional laboratory-first discovery. A 2024 study published in Cell used machine learning to examine data from 63,410 metagenomes and 87,920 microbial genomes. It produced the AMPSphere catalogue containing 863,498 non-redundant candidate antimicrobial peptides.
Researchers synthesized 100 candidates for testing. Seventy-nine showed activity in laboratory tests and 63 targeted pathogens, including drug-resistant bacteria. The peptides generally acted by disrupting bacterial membranes. The result demonstrates the value of computational screening, but it does not mean that all predicted molecules are ready to become medicines. Safety, selectivity, dosage, delivery, effectiveness in living organisms, manufacturing and clinical trials remain essential.
Emerging Solutions and Their Limits
- New antibiotics: innovation is necessary, but every new medicine must be protected through responsible use.
- Antimicrobial peptides: naturally occurring or designed peptides may target resistant bacteria, though stability, toxicity, delivery and production cost remain challenges.
- Bacteriophages: viruses that infect specific bacteria offer a potential targeted treatment, but standardisation, matching and regulation require further development.
- Rapid diagnostics: faster identification of pathogens and resistance can reduce unnecessary broad-spectrum treatment.
- Vaccines: preventing bacterial and viral infections reduces antimicrobial consumption and transmission.
- Surveillance and genomic sequencing: timely data help detect emerging resistance and guide treatment and policy.
What More Needs to Be Done?
- Make stewardship routine: hospitals should maintain antibiotic policies, review prescriptions, measure consumption and provide feedback to clinicians.
- Expand diagnostic capacity: strengthen microbiology laboratories and make reliable point-of-care tests more accessible.
- Enforce prescription rules: prevent non-prescription sales while ensuring that patients who genuinely need antimicrobials can obtain them.
- Invest in prevention: improve water, sanitation, vaccination, hospital hygiene and animal-health systems.
- Control pollution: set and enforce discharge standards for pharmaceutical plants, hospitals, farms and municipal wastewater.
- Improve One Health surveillance: connect human, animal, food and environmental data rather than maintaining isolated systems.
- Support research with access safeguards: encourage new medicines and diagnostics while planning affordability and responsible use.
- Build public awareness: explain why antibiotics do not treat viral infections and why prescriptions must be followed correctly.
UPSC Exam Relevance
- Prelims: meaning of AMR, antibiotics and antimicrobials; superbugs; One Health; WHO; ICMR; GLASS; National Action Plan on AMR.
- GS Paper II: public health, government policy, healthcare capacity and international institutions.
- GS Paper III: science and technology, biotechnology, environmental pollution, agriculture and disaster-like health risks.
- Essay and Interview: responsible innovation, cooperative federalism, behavioural change and balancing access to medicines with stewardship.
Key Takeaway
Antimicrobial resistance is not simply a problem of finding stronger drugs. It is produced by the interaction of medicine use, weak infection control, animal production, environmental pollution and gaps in governance. India's most durable response will combine prevention, diagnosis, rational treatment, One Health surveillance, pollution control and carefully governed innovation.
Authoritative References
Frequently asked questionsFrequently asked questions
What is antimicrobial resistance?
Antimicrobial resistance occurs when bacteria, viruses, fungi or parasites change and no longer respond to medicines, making infections harder to treat and increasing the risk of severe illness, spread and death.
Why is antimicrobial resistance increasing in India?
Major drivers include misuse and overuse in people and animals, self-medication, prescribing without adequate diagnostics, weak infection control, poor sanitation and antimicrobial residues entering the environment.
How is India addressing antimicrobial resistance?
India uses a One Health approach through NAP-AMR 2.0 for 2025–2029, ICMR surveillance, antimicrobial stewardship, infection prevention, prescription controls, regulation of agricultural use and research into medicines and diagnostics.